精氨酸二甲基化升高与肌萎缩侧索硬化进展及预后相关
该研究检测了ALS患者死后脊髓中PRMT1及不对称二甲基化蛋白的免疫反应性,并用液相色谱-串联质谱法测定了52例ALS患者脑脊液中总L-精氨酸及甲基化精氨酸残基浓度。结果显示ALS患者PRMT1和ASYM免疫反应性升高,脑脊液ADMA浓度显著高于疾病对照,ADMA/L-精氨酸比值与12个月ALS功能评定量表下降变化相关,且为总生存的独立预测因素,高比值预示预后不良。
要点
- ALS患者脊髓中PRMT1和ASYM免疫反应性升高。
- ALS患者脑脊液ADMA浓度显著高于疾病对照。
- 脑脊液ADMA/L-精氨酸比值可预测ALS疾病进展和预后。
核心结论
- ALS患者存在精氨酸二甲基化增强,脑脊液ADMA/L-精氨酸比值可预测疾病进展和预后。
研究设计与样本
- 研究比较ALS患者死后脊髓中PRMT1及ASYM的免疫反应性,并用液相色谱-串联质谱法测定52例ALS患者脑脊液中总L-精氨酸及甲基化精氨酸残基浓度,分析其与疾病进展和预后的关系。
主要发现
- ALS患者脊髓中PRMT1免疫反应性升高(p < 0.0001),ASYM免疫反应性升高(p = 0.005)。
- ALS患者脑脊液ADMA浓度显著高于疾病对照。
- 脑脊液ADMA/L-精氨酸比值与测量后12个月ALS功能评定量表下降变化相关(r = 0.406,p = 0.010)。
- Cox比例风险模型显示ADMA/L-精氨酸比值为总生存的独立预测因素。
- 高ADMA/L-精氨酸比值预示预后不良,即使在用力肺活量百分比正常组中亦然。
临床怎么用
- 脑脊液ADMA/L-精氨酸比值或可作为ALS疾病进展和预后的生物标志物,用于风险分层。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate whether arginine methylation is altered in patients with amyotrophic lateral sclerosis (ALS) and how it affects disease severity, progression, and prognosis. METHODS: We compared the immunoreactivity of protein arginine methyltransferase 1 (PRMT1) and its products, asymmetric dimethylated proteins (ASYM), in postmortem spinal cord. We also measured the concentrations of total l-arginine and methylated arginine residues, including asymmetric dimethyl l-arginine (ADMA), symmetric dimethyl arginine, and monomethyl arginine, in CSF samples from 52 patients with ALS using liquid chromatography-tandem mass spectrometry, and we examined their relationship with the progression and prognosis of ALS. RESULTS: The immunoreactivity of both PRMT1 (p < 0.0001) and ASYM (p = 0.005) was increased in patients with ALS. The concentration of ADMA in CSF was substantially higher in patients with ALS than in disease controls. The ADMA/l-arginine ratio was correlated with the change of decline in the ALS Functional Rating Scale at 12 months after the time of measurement (r = 0.406, p = 0.010). A Cox proportional hazards model showed that the ADMA/l-arginine ratio was an independent predictor for overall survival. Moreover, a high ADMA/l-arginine ratio predicted poor prognosis, even in a group with normal percentage forced vital capacity. CONCLUSION: There was an enhancement of arginine dimethylation in patients with ALS, and the ADMA/l-arginine ratio predicted disease progression and prognosis in such patients.
引用
- Ikenaka K, Atsuta N, Maeda Y, et al. Increase of arginine dimethylation correlates with the progression and prognosis of ALS. Neurology. 2019. PMID: 30867270. doi:10.1212/WNL.0000000000007311
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。